Carmell Therapeutics Stock Price Prediction

CTCX Stock   0.28  0.02  7.69%   
At this time, the RSI of Carmell Therapeutics' share price is approaching 41 suggesting that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Carmell Therapeutics, making its price go up or down.

Oversold Vs Overbought

41

 
Oversold
 
Overbought
The successful prediction of Carmell Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Carmell Therapeutics, which may create opportunities for some arbitrage if properly timed.
Using Carmell Therapeutics hype-based prediction, you can estimate the value of Carmell Therapeutics from the perspective of Carmell Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Carmell Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Carmell because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Carmell Therapeutics after-hype prediction price

    
  USD 0.28  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Carmell Therapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Carmell Stock please use our How to Invest in Carmell Therapeutics guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Carmell Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.010.2714.03
Details
Naive
Forecast
LowNextHigh
0.010.3414.10
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.150.330.51
Details

Carmell Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Carmell Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Carmell Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Carmell Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Carmell Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Carmell Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Carmell Therapeutics' historical news coverage. Carmell Therapeutics' after-hype downside and upside margins for the prediction period are 0.01 and 14.04, respectively. We have considered Carmell Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.28
0.28
After-hype Price
14.04
Upside
Carmell Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Carmell Therapeutics is based on 3 months time horizon.

Carmell Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Carmell Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Carmell Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Carmell Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.15 
13.76
 0.00  
 0.00  
2 Events / Month
7 Events / Month
In a few days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.28
0.28
0.00 
137,600  
Notes

Carmell Therapeutics Hype Timeline

Carmell Therapeutics is currently traded for 0.28. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Carmell is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is currently at -0.15%. %. The volatility of related hype on Carmell Therapeutics is about 275200.0%, with the expected price after the next announcement by competition of 0.28. About 34.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.91. Some equities with similar Price to Book (P/B) outperform the market in the long run. Carmell Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in a few days.
Check out Carmell Therapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Carmell Stock please use our How to Invest in Carmell Therapeutics guide.

Carmell Therapeutics Related Hype Analysis

Having access to credible news sources related to Carmell Therapeutics' direct competition is more important than ever and may enhance your ability to predict Carmell Therapeutics' future price movements. Getting to know how Carmell Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Carmell Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
ZVSAZyVersa Therapeutics(0.1)4 per month 0.00 (0.16) 7.57 (9.60) 78.93 
SONNSonnet Biotherapeutics Holdings 1.15 6 per month 0.00 (0.17) 12.31 (9.79) 37.58 
REVBRevelation Biosciences(0.03)3 per month 0.00 (0.11) 8.97 (7.83) 34.52 
QNRXQuoin Pharmaceuticals Ltd(0.01)11 per month 6.66  0.03  17.65 (9.68) 74.46 
ALLRAllarity Therapeutics(0.08)28 per month 0.00 (0.28) 10.85 (16.11) 41.48 
VRAXVirax Biolabs Group(0.81)3 per month 0.00 (0.12) 9.65 (12.90) 61.28 
BDRXBiodexa Pharmaceticals(0.01)22 per month 0.00 (0.1) 11.91 (17.24) 97.78 
PALIPalisade Bio 0.03 7 per month 0.00 (0.11) 5.97 (8.55) 24.25 
UNCYUnicycive Therapeutics(0.05)7 per month 4.33  0.18  10.26 (7.41) 29.22 
IMMXImmix Biopharma(0.04)4 per month 4.55 (0.02) 9.38 (8.22) 32.68 

Carmell Therapeutics Additional Predictive Modules

Most predictive techniques to examine Carmell price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Carmell using various technical indicators. When you analyze Carmell charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Carmell Therapeutics Predictive Indicators

The successful prediction of Carmell Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Carmell Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Carmell Therapeutics based on analysis of Carmell Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Carmell Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Carmell Therapeutics's related companies.

Story Coverage note for Carmell Therapeutics

The number of cover stories for Carmell Therapeutics depends on current market conditions and Carmell Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Carmell Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Carmell Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Carmell Therapeutics Short Properties

Carmell Therapeutics' future price predictability will typically decrease when Carmell Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Carmell Therapeutics often depends not only on the future outlook of the potential Carmell Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Carmell Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding11 M
Cash And Short Term Investments2.9 M
Shares Float13 M

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.